Abstract
Developing stem cell translational medicine and regulating the clinical translation of stem cells will pose great challenges in the future. This article will present three cases in China and show how each mobilized various strategies to bring stem cell science to treatments and commercialization and the problems encountered in the process. The case studies will show that translational research involves multiple interactions between different actors and requires new modes of governance. In China, as in other countries, the regulatory context for translational stem cell research is far from clear, but the absence of state regulation has not led to a “Wild East” regulatory constellation, but rather to individualized regulatory strategies by a variety of stakeholders.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
